1. Home
  2. TSHA

TSHA

Taysha Gene Therapies Inc.

Logo Taysha Gene Therapies Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 9:40am EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Founded: 2019 Country:
United States
United States
Employees: N/A City: DALLAS
Market Cap: 501.2M IPO Year: 2020
Target Price: $6.88 AVG Volume (30 days): 2.7M
Analyst Decision: Strong Buy Number of Analysts: 8
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.96 EPS Growth: N/A
52 Week Low/High: $0.50 - $3.89 Next Earning Date: 05-09-2024
Revenue: $15,451,000 Revenue Growth: 517.55%
Revenue Growth (this year): -64.35% Revenue Growth (next year): -62.96%

Share on Social Networks: